AngioDynamics, Inc. (ANGO)
NASDAQ: ANGO · Real-Time Price · USD
12.29
-0.11 (-0.89%)
At close: Nov 26, 2025, 4:00 PM EST
12.30
+0.01 (0.08%)
After-hours: Nov 26, 2025, 4:30 PM EST
AngioDynamics Revenue
AngioDynamics had revenue of $75.71M in the quarter ending August 31, 2025, with 12.18% growth. This brings the company's revenue in the last twelve months to $300.72M, up 2.73% year-over-year. In the fiscal year ending May 31, 2025, AngioDynamics had annual revenue of $292.50M, down -3.76%.
Revenue (ttm)
$300.72M
Revenue Growth
+2.73%
P/S Ratio
1.68
Revenue / Employee
$445,508
Employees
675
Market Cap
506.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 292.50M | -11.42M | -3.76% |
| May 31, 2024 | 303.91M | -34.84M | -10.28% |
| May 31, 2023 | 338.75M | 22.53M | 7.13% |
| May 31, 2022 | 316.22M | 25.21M | 8.66% |
| May 31, 2021 | 291.01M | 26.85M | 10.17% |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ANGO News
- 16 days ago - AngioDynamics, Inc. (ANGO) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - AngioDynamics to Participate in the UBS Global Healthcare Conference - Business Wire
- 6 weeks ago - AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List - Business Wire
- 7 weeks ago - AngioDynamics: Discounted Sales Multiple With Real Growth Engines - Seeking Alpha
- 7 weeks ago - Why Did AngioDynamics Stock Pop Today? - The Motley Fool
- 2 months ago - AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results - Benzinga
- 2 months ago - AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum - Business Wire